Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Regenerative MedicineCell Therapy

PUBLISHER: Roots Analysis | PRODUCT CODE: 1490318

Cover Image

PUBLISHER: Roots Analysis | PRODUCT CODE: 1490318

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigen, Target Indication, Key Geographies, Sales Forecast of Drugs and Leading Players

PUBLISHED:
PAGES: 640 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4799
PDF (One-Location Site License)
USD 6999
PDF (Department License)
USD 10599
PDF (Enterprise License)
USD 17999

Add to Cart

Description

Table of Contents

List of Tables

CAR T-cell therapy market (5th Edition): Industry Trends and Global Forecasts, Till 2035: Distribution by Target Antigens (CD19, BCMA, CD20, CD19/22, and Other Target Antigens), Target Indication (Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, and Others), Key Geographies (North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa, and Rest of the World), Sales Forecast of Drugs and Leading Players

The CAR T Cell Therapy Market is valued at USD 4.6 billion in 2024 growing at a CAGR of 20% during the forecast period 2024-2035.

Cancer stands as a leading cause of mortality worldwide, with the World Health Organization (WHO) reporting 10 million cancer-related deaths in 2020 alone. Projections suggest that by 2040, the global cancer burden will escalate, adding an estimated 27.5 million new cases, placing immense physical, emotional, and financial strain on affected individuals, families, communities, and national health systems. Currently, conventional treatment modalities such as chemotherapy, radiation therapy, and surgery are utilized for various cancers. However, despite the array of treatment options aimed at controlling disease progression and halting the spread of malignant cells, achieving lasting remission remains challenging. To cater to the limitations of conventional treatments, active initiatives have been launched to develop more targeted anti-cancer therapies. Among these, CAR T cell therapies have emerged as a promising option due to their ability to eliminate tumor cells with minimal treatment-related side effects. Immunotherapies leverage the body's immune system or its components to combat cancer. Various classes of immunotherapies, including therapeutic cancer vaccines, oncolytic viruses, cytokines, immune checkpoint inhibitors, and certain whole cell-based therapies, have emerged as an alternative for cancer management and treatment.

CAR-T cell therapy, a recent addition to anticancer interventions, has shown significant success alongside targeted antibody-based therapeutics like monoclonal and conjugated antibodies. This highly specific form of cell therapy, harnessing the versatile effector machinery of the human immune system, has revolutionized cancer treatment globally. Ongoing research in this field continues to uncover novel molecular targets, bolstering the research pipelines of companies in this domain. With a growing number of CAR T cell therapies under development and entering the market, the CAR T cell therapy market is poised to become one of the most valuable segments within the biopharmaceutical industry.

Key Market Segments

Target Indication

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
  • Chronic Lymphocytic Leukemia
  • Generalized Myasthenia Gravis
  • Hodgkin's Lymphoma
  • Multiple Myeloma
  • Non-Hodgkin's Lymphoma
  • Ovarian Cancer
  • Renal Cell Carcinoma
  • Others

Target Antigen

CD19

BCMA

CD19 / CD22

  • Others

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and North Africa
  • Rest of the World

Research Coverage:

  • A detailed analysis of the current market landscape of CAR-T cell therapies with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD19 / CD22, GPC3, NY-ESO-1 and others), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of CAR T cell therapy. Further, this chapter also includes developer landscape analysis based on the relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia-Pacific).
  • Comprehensive assessment of key insights derived from the study featuring a competitive analysis, highlighting the popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR T cell therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.
  • A comprehensive assessment of the completed, ongoing and planned clinical studies related to CAR T cell therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.
  • An insightful analysis highlighting the key opinion leaders (KOLs) featuring an assessment of the principal investigators of clinical trials related to CAR-T therapies, considering them to be KOLs, who are actively involved in R&D of CAR T cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.
  • Elaborate company profiles of leading players in this domain. Each company profile includes a company overview and brief description of the product portfolio, technology portfolio, recent developments related to CAR-T cell therapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.
  • An analysis of different types of partnership that have been inked between several stakeholders in this domain, on various type of partnership such as, R&D agreements, license agreements (specific to technology platforms and therapy candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures and others.
  • An analysis of the funding and investment analysis that have been made into CAR T cell therapy companies that have proprietary therapies / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants and debt financing.
  • An in-depth analysis of patents related to CAR T cell therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted patents, patent applications and others), publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents filed / granted) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents.
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate assessment of various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a CAR-T cell therapy that is likely to be marketed in the coming years.
  • An in-depth analysis of various factors that can influence the growth of CAR T cell therapy market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.
  • A detailed estimate of the current market size, opportunity and the future growth potential of the CAR T cell therapy market over the next 12 years. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period till 2035. The report also features the likely distribution of the current and forecasted opportunity within this market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.
  • Comprehensive predictions of the current and future CAR T cell therapy market across type of target indication, such as non-Hodgkin lymphoma, multiple myeloma, acute lymphoblastic leukemia, chronic lymphocytic leukemia, Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, generalized myasthenia gravis and renal cell carcinoma).
  • Comprehensive projections of the current and future CAR T-cell therapy market across types of target antigen, such as CD19, BCMA, CD19 / CD22 and others.
  • Detailed projections of the current and future CAR T cell therapy market across leading players.
  • Detailed projections of the current and future CAR T-cell therapy market across key geographical regions, such as North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa and Rest of the World.
  • A review of the key promotional strategies being adopted by the developers of the approved CAR T cell therapies, namely Tisagenlecleucel-T (KYMRIAH(R)), Axicabtagene ciloleucel (YESCARTA(R)), Brexucabtagene Autoleucel (TECARTUS(TM)), Lisocabtagene maraleucel (Breyanzi(R)), Idecabtagene Vicleucel (Abecma(TM)), Ciltacabtagene Autoleucel (CARVYKTI(TM)) and others.

Key Benefits of Buying this Report

  • The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
  • Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
  • The report provides stakeholders with a pulse on the CAR T Cell Therapy Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

  • Alaunos Therapeutics
  • Autolus
  • Abelzeta Pharma
  • Bluebird Bio
  • Bristol Myers Squibb
  • Carsgen Therapeutics
  • Cellectis
  • Gilead Sciences
  • Innovative Cellular Therapeutics
  • Kuur Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai GeneChem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Wellington Zhaotai Therapies
Show more
Product Code: RA100389

TABLE OF CONTENTS

Table Of Contents

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
  • 2.3. Project Methodology
  • 2.4. Forecast Methodology
  • 2.5. Robust Quality Control
  • 2.6. Key Market Segmentations
  • 2.7. Key Considerations
    • 2.7.1. Demographics
    • 2.7.2. Economic Factors
    • 2.7.3. Government Regulations
    • 2.7.4. Supply Chain
    • 2.7.5. COVID Impact / Related Factors
    • 2.7.6. Market Access
    • 2.7.7. Healthcare Policies
    • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

  • 3.1. Chapter Overview
  • 3.2. Market Dynamics
    • 3.2.1. Time Period
      • 3.2.1.1. Historical Trends
      • 3.2.1.2. Current and Forecasted Estimates
    • 3.2.2. Currency Coverage
      • 3.2.2.1. Overview of Major Currencies Affecting the Market
      • 3.2.2.2. Impact of Currency Fluctuations on the Industry
    • 3.2.3. Foreign Exchange Impact
      • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
      • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 3.2.4. Recession
      • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
      • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
    • 3.2.5. Inflation
      • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

  • 5.1. Chapter Overview
  • 5.2. Overview of T-cell Immunotherapies
    • 5.2.1. Historical Evolution
    • 5.2.2. Key Considerations for Developing T-cell Immunotherapies
    • 5.2.3. Strategies Employed for the Redirection of T-cells
    • 5.2.4. Manufacturing of Engineered T-cells
  • 5.3. Chimeric Antigen Receptor T-cell (CAR-T) Therapy
    • 5.3.1. Development History
    • 5.3.2. Structure of CAR
      • 5.3.2.1. Ectodomain
      • 5.3.2.2. Transmembrane (TM) Domain
      • 5.3.2.3. Endodomain
    • 5.3.3. Development of CAR-T Cells
    • 5.3.4. Universal CAR-T Cells
    • 5.3.5. Route of Administration
    • 5.3.6. Challenges Associated with CAR-T Cell Therapies
      • 5.3.6.1. Competitive Risks
      • 5.3.6.2. Clinical Risks
      • 5.3.6.3. Regulatory Risks
      • 5.3.6.4. Commercial Risks
  • 5.4. Concluding Remarks

6. CAR-T CELL THERAPIES: MARKET LANDSCAPE

  • 6.1. Chapter Overview
  • 6.2. CAR-T Cell Therapies: Market Landscape
    • 6.2.2. Analysis by Stage of Development
    • 6.2.3. Analysis by Type of Therapy
    • 6.2.4. Analysis by Target Antigen
    • 6.2.5. Analysis by Target Indication
    • 6.2.6. Analysis by Therapeutic Area
    • 6.2.7. Analysis by Stage of Development and Therapeutic Area
    • 6.2.8. Analysis by Source of T-cells
    • 6.2.9. Analysis by Stage of Development and Source of T-cells
    • 6.2.10. Analysis by Route of Administration
    • 6.2.11. Analysis by Dosage Regimen
    • 6.2.12. Analysis by Target Patient Population
    • 6.2.13. Most Active Industry Players: Analysis by Number of Therapies
    • 6.2.14. Most Active Non-Industry Players: Analysis by Number of Therapies
  • 6.3. CAR-T Cell Therapies: Overall Developer Landscape
    • 6.3.1. Analysis by Year of Establishment
    • 6.3.2. Analysis by Company Size
    • 6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS

  • 7.1. Chapter Overview
  • 7.2. CAR-T Cell Therapies: Popular Target Antigens
    • 7.2.1. Popular Targets for Hematological Malignancies
    • 7.2.2. Popular Targets for Solid Tumors
  • 7.3. CAR-T Therapies: CAR Construct Analysis
    • 7.3.1. Analysis by Generation of CAR
    • 7.3.2. Analysis by Type of scFv Antibody Used
    • 7.3.3. Analysis by Type of Virus Used
    • 7.3.4. Analysis by Type of Gene Transfer Method Used
    • 7.3.5. Analysis by Type of Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. CAR-T Cell Therapies: Clinical Trial Analysis
    • 8.3.1. Analysis by Trial Registration Year
    • 8.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
    • 8.3.3. Analysis by Trial Phase
    • 8.3.4. Analysis of Enrolled Patient Population by Trial Phase
    • 8.3.5. Analysis by Trial Registration Year and Trial Phase
    • 8.3.6. Analysis by Trial Status
    • 8.3.7. Analysis by Patient Gender
    • 8.3.8. Analysis by Therapeutic Area
    • 8.3.9. Analysis by Study Design
    • 8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
    • 8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
    • 8.3.13. Analysis by Geography

9. KEY OPINION LEADERS

  • 9.1. Chapter Overview
  • 9.2. Assumptions and Key Parameters
  • 9.3. Methodology
  • 9.4. CAR-T Cell Therapies: Key Opinion Leaders
    • 9.4.1. Analysis by Type of Organization
    • 9.4.2. Analysis by Affiliated Organization
    • 9.4.3. Analysis by Geographical Location of KOLs
    • 9.4.4. KOL Activeness versus KOL Strength
    • 9.4.5. Most Prominent KOLs: Analysis by RA score
    • 9.4.6. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. COMPANY PROFILES

  • 10.1. Chapter Overview
  • 10.2. Autolus
  • 10.3. Bluebird Bio
  • 10.4. Bristol Myers Squibb
  • 10.5. CARsgen Therapeutics
  • 10.6. Cellectis
  • 10.7. Gilead Sciences
  • 10.8. Innovative Cellular Therapeutics
  • 10.9. Noile-Immune Biotech
  • 10.10. Novartis
  • 10.11. Sinobioway Cell Therapy
  • 10.12. Takara Bio
  • 10.13. Wellington Zhaotai Therapies

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. CAR-T Cell Therapies: Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Year and Type of Partnership
    • 11.3.4. Analysis by Type of Partner
    • 11.3.5. Most Popular Therapies: Analysis by Number of Partnerships
    • 11.3.6. Most Active Industry Players: Analysis by Number of Partnerships
    • 11.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships
    • 11.3.8. Analysis by Geography
      • 11.3.8.1. Intercontinental and Intracontinental Agreements
      • 11.3.8.2. International and Local Agreements

12. FUNDING AND INVESTMENTS ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Types of Funding
  • 12.3. CAR-T Cell Therapies: Funding and Investment Analysis
    • 12.3.1. Analysis by Year of Funding
    • 12.3.2. Analysis of Amount Invested
    • 12.3.3. Analysis by Type of Funding
    • 12.3.4. Analysis by Amount Invested and Type of Funding
    • 12.3.5. Analysis by Amount Invested by year and Type of Funding Analysis by Type of Investor
    • 12.3.6. Analysis by Geography
    • 12.3.7. Most Active Players
    • 12.3.8. Leading Investors: Analysis by Number of Funding Instances

13. PATENT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Scope and Methodology
  • 13.3. CAR-T Cell Therapies: Patent Analysis
    • 13.3.1. Analysis by Patent Publication Year
    • 13.3.2. Analysis by Patent Application Year
    • 13.3.3. Analysis of Granted Patents and Patent Applications by Publication Year
    • 13.3.4. Analysis by Patent Jurisdiction
    • 13.3.5. Analysis by CPC Symbols
    • 13.3.6. Analysis by Type of Applicant
    • 13.3.7. Leading Industry Players: Analysis by Number of Patents
    • 13.3.8. Leading Non-Industry Players: Analysis by Number of Patents
    • 13.3.9. Leading Patent Assignees: Analysis by Number of Patents
  • 13.4. Patent Benchmarking Analysis
    • 13.4.1. Analysis by Patent Characteristics
  • 13.5. Patent Valuation
  • 13.6. Leading Patents by Number Of Citations

14. CASE STUDY: CELL THERAPY MANUFACTURING

  • 14.1. Chapter Overview
  • 14.2. Overview of Cell Therapy Manufacturing
  • 14.3. Cell Therapy Manufacturing Models
    • 14.3.1. Centralized Manufacturing Model
    • 14.3.2. Decentralized Manufacturing Model
  • 14.4. Scalability of Cell Therapy Manufacturing Processes
    • 14.4.1. Scale-Up
    • 14.4.2. Scale-Out
  • 14.5. Types of Cell Therapy Manufacturers
  • 14.6. Key Challenges Related to Manufacturing of Cell Therapies
  • 14.7. Key Considerations for Cell Therapy Manufacturing
    • 14.7.1. Characterization
    • 14.7.2. Cost of Goods
  • 14.8. Automation of Cell Therapy Manufacturing Process
  • 14.9. Cell Therapy Manufacturing Supply Chain
  • 14.10. Comparison of Players Having In-house Capabilities and Contract Manufacturers
  • 14.11. Regulatory Landscape
  • 14.12. Future Perspectives

15. COST PRICE ANALYSIS

  • 15.1 Chapter Overview
  • 15.2. Factors Contributing to the High Price of Cell / Gene Therapies
  • 15.3. Pricing Models for T-cell Immunotherapies
    • 15.3.1. Based on Associated Costs
    • 15.3.2. Based on Availability of Competing Products
    • 15.3.3. Based on Patient Population
    • 15.3.4. Based on Opinions of Industry Experts
  • 15.4. Reimbursement related Considerations for T-cell Immunotherapies
    • 15.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

16. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

  • 16.1. Chapter Overview
  • 16.2. Market Drivers
  • 16.3. Market Restraints
  • 16.4. Market Opportunities
  • 16.5. Market Challenges
  • 16.6. Conclusion

17. GLOBAL CAR-T CELL THERAPY MARKET

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Future Estimates (2024-2035), till 2035
  • 17.4. Scenario Analysis
    • 17.4.1. Conservative Scenario
    • 17.4.2. Optimistic Scenario
  • 17.5. Key Market Segmentations

18. CAR-T CELL THERAPY MARKET, BY TARGET ANTIGEN

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. CAR-T Cell Therapies Market: Distribution by Type Target Antigen, 2024 and 2035
    • 18.3.1. CART-T Cell Therapies Market for CD19: Forecasted Estimates (2024-2035)
    • 18.3.2. CART-T Cell Therapies Market FOR BCMA: Forecasted Estimates (2024-2035)
    • 18.3.3. CART-T Cell Therapies Market FOR CD20: Forecasted Estimates (2024-2035)
    • 18.3.4. CART-T Cell Therapies Market for CD19 / CD22: Forecasted Estimates (2025-2035)
    • 18.3.5. CAR-T Cell Therapies Market for Other Target Antigens: Forecasted Estimates (2028-2035)
  • 18.4. Data Triangulation and Validation

19. CAR-T CELL THERAPY MARKET, BY TARGET INDICATION

  • 19.1. Chapter Overview
  • 19.2. Key Assumptions and Methodology
  • 19.3. CAR-T Cell Therapies Market: Distribution by Target Indication, 2024 and 2035
    • 19.3.1. CAR-T Cell Therapies Market for Multiple Myeloma: Forecasted Estimates (2024-2035)
    • 19.3.2. CAR-T Cell Therapies Market for Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
    • 19.3.3. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035)
    • 19.3.4. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
    • 19.3.5. CAR-T Cell Therapies Market for Diffuse Large B-Cell Lymphoma and Large B-Cell Lymphoma: Forecasted Estimates (2024-2035)
    • 19.3.6. CAR-T Cell Therapies Market for Acute Lymphoblastic Leukemia/ B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035)
    • 19.3.7. CAR-T Cell Therapies Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035)
    • 19.3.8. CAR-T Cell Therapies Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035)
    • 19.3.9. CAR-T Cell Therapies Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035)
    • 19.3.10. CAR-T Cell Therapies Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035)
    • 19.3.11. CAR-T Cell Therapies Market for Renal Transplantation: Forecasted Estimates (2030-2035)
    • 19.3.12. CAR-T Cell Therapies Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035)
    • 19.3.13. CAR-T Cell Therapies Market for Ovarian / Endometrial cancer: Forecasted Estimates (2028-2035)
    • 19.3.14. CAR-T Cell Therapies Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035)
    • 19.3.15. CAR-T Cell Therapies Market for Follicular Lymphoma: Forecasted Estimates (2024-2035)
    • 19.3.16. CAR-T Cell Therapies Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035)
  • 19.6. Data Triangulation and Validation

20. CAR-T CELL THERAPY MARKET: DISTRIBUTION BY KEY GEOGRAPHICAL REGIONS

  • 20.1. Chapter Overview
  • 20.2. Key Assumptions and Methodology
  • 20.3. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
    • 20.3.1. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035)
    • 20.3.2. CAR-T Cell Therapy Market for Europe: Forecasted Estimates (2024-2035)
    • 20.3.3. CAR-T Cell Therapy Market for Asia-Pacific: Forecasted Estimates (2024-2035)
    • 20.3.4. CAR-T Cell Therapy Market for Latin America: Forecasted Estimates (2024-2035)
    • 20.3.5. CAR-T Cell Therapy Market for Middle East and North Africa: Forecasted Estimates (2024-2035)
    • 20.3.6. CAR-T Cell Therapy Market for Rest of the World: Forecasted Estimates (2024-2035)
  • 20.4. Data Triangulation and Validation

21. CAR-T THERAPY MARKET, SALES FORECAST OF DRUGS

  • 21.1. Chapter Overview
  • 21.2. Key Assumptions and Methodology
  • 21.3. Commercialized CAR-T Cell Therapies: Sales Forecast
    • 21.3.1. Kymriah (Tisagenlecleucel-T) Sales Forecast
    • 21.3.2. Yescarta (axicabtagene ciloleucel) Sales Forecast
    • 21.3.3. Tecartus (Brexucabtagene Autoleucel) Sales Forecast
    • 21.3.4. Abecma (Idecabtagene Vicleucel / bb211211) Sales Forecast
    • 21.3.5. CARVYKTI (LCAR-B38M CAR-T / JNJ-6821845218 / Ciltacabtagene Autoleucel) Sales Forecast
    • 21.3.6. BREYANZI (Lisocabtagene maraleucel, JCAR017) Sales Forecast
    • 21.3.7. Carteyva (Relmacabtagene autoleucel / JWCAR0219) Sales Forecast
    • 21.3.8. NexCART Sales Forecast
    • 21.3.9. Fucaso (Equecabtagene Autoleucel) Sales Forecast
    • 21.3.10. Inaticabtagene Autoleucel CNCT19 / HY001Sales Forecast
    • 21.3.11. Zevorcabtagene autoleucel (CT053) Sales Forecast
  • 21.4 Clinical CAR-T Cell Therapies: Sales Forecast
    • 21.4.1. CAR-BCMA T cells Sales Forecast
    • 21.4.2. CAR-T-CD19 Cells Sales Forecast
    • 21.4.3. Descartes-08 Sales Forecast
    • 21.4.4. Zamtocabtagene Autoleucel (MB-CART21019.1) Sales Forecast
    • 21.4.5. CAR-T ddBCMA Sales Forecast
    • 21.4.6. CRG-02121 cells Sales Forecast
    • 21.4.7. CT041 Sales Forecast
    • 21.4.8. ALLO-501A / ALLO-501 Sales Forecast
    • 21.4.9. ALLO-605 Sales Forecast
    • 21.4.10. Descartes-25 Sales Forecast
    • 21.4.11. AUTO1 Sales Forecast
    • 21.4.12. AUTO3 (CD19/2121 CAR-T) Sales Forecast
    • 21.4.13. AUTO4 (CD19/2121 CAR-T) Sales Forecast
    • 21.4.14. CD19-CAR-T Sales Forecast
    • 21.4.15. Humanized CD19-CAR-T Sales Forecast
    • 21.4.16. IM19 CAR-T Sales Forecast
    • 21.4.17. CCT301 CAR-T Sales Forecast
    • 21.4.18. CARCIK-CD19 Sales Forecast
    • 21.4.19. CD123 CAR-T cells Sales Forecast
    • 21.4.20. BCMA CAR-T Sales Forecast
    • 21.4.21. CD19/CD22-CAR-T Sales Forecast
    • 21.4.22. GC012F (Dual CAR-BCMA-19) Sales Forecast
    • 21.4.23. CD19/CD210-CART Sales Forecast
    • 21.4.24. CD7 CAR-T Sales Forecast
    • 21.4.25. Anti-FLT3 CAR-T / TAA05 Sales Forecast
    • 21.4.26. Anti-ALPP CAR-T Cells Sales Forecast
    • 21.4.27. WU CART 007 Sales Forecast
    • 21.4.28. CTX110 Sales Forecast
    • 21.4.29. TX2100-TR101 Sales Forecast
    • 21.4.30. ALETA-001 Sales Forecast
    • 21.4.31. PBCAR0191 Sales Forecast
  • 21.5. Data Triangulation and Validation

22. CAR-T CELL THERAPY MARKET: SALES FORECAST OF LEADING PLAYERS

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. CAR-T Cell Therapies: Leading Players
    • 22.3.1. Gilead Sciences Sales Forecast
    • 22.3.2. Bristol Myers Squibb Sales Forecast
    • 22.3.3. Novartis Sales Forecast
    • 22.3.4. Janssen Sales Forecast
    • 22.3.5. JW Therapeutics Sales Forecast
  • 22.4. Data Triangulation and Validation

23. PROMOTIONAL ANALYSIS

  • 23.1. Chapter Overview
  • 23.2. Channels Used for Promotional Campaigns
  • 23.3. Summary of Product Website Analysis
  • 23.4. Summary of Patient Support Services and Informative Downloads
  • 23.5. Kymriah: Promotional Analysis
    • 23.5.1. Drug Overview
    • 23.5.2. Product Website Analysis
      • 23.5.2.1. Message for Healthcare Professionals
      • 23.5.2.2. Message for Patients
      • 23.5.2.3. Informative Downloads
    • 23.5.3. Patient Support Services
  • 23.6. Yescarta: Promotional Analysis
    • 23.6.1. Drug Overview
    • 23.6.2. Product Website Analysis
      • 23.6.2.1. Message for Healthcare Professionals
      • 23.6.2.2. Message for Patients
      • 23.6.2.3. Informative Downloads
    • 23.6.3. Patient Support Services
  • 23.7. Tecartus: Promotional Analysis
    • 23.7.1. Drug Overview
    • 23.7.2. Product Website Analysis
      • 23.7.2.1. Message for Healthcare Professionals
      • 23.7.2.2. Message for Patients
      • 23.7.2.3. Informative Downloads
    • 23.7.3. Patient Support Services
  • 23.8. Breyanzi: Promotional Analysis
    • 23.8.1. Drug Overview
    • 23.8.2. Product Website Analysis
      • 23.8.2.1. Message for Healthcare Professionals
      • 23.8.2.2. Message for Patients
      • 23.8.2.3. Informative Downloads
    • 23.8.3. Patient Support Services
  • 23.9. Abecma: Promotional Analysis
    • 23.9.1. Drug Overview
    • 23.9.2. Product Website Analysis
      • 23.9.2.1. Message for Healthcare Professionals
      • 23.9.2.2. Message for Patients
      • 23.9.2.3. Informative Downloads
    • 23.9.3. Patient Support Services
  • 23.10. Carvykti: Promotional Analysis
    • 23.10.1. Drug Overview
    • 23.10.2. Product Website Analysis
      • 23.10.2.1. Message for Healthcare Professionals
      • 23.10.2.2. Message for Patients
      • 23.10.2.3. Informative Downloads
    • 23.10.3. Patient Support Services

24. EXECUTIVE INSIGHTS

  • 24.1. Chapter Overview
  • 24.2. Atara Biotherpeutics
    • 24.2.1. Interview Transcript
  • 24.3. Glycostem Therapeutics
    • 24.3.1. Interview Transcript
  • 24.4. Gracell Biotechnologies
    • 24.4.1. Interview Transcript
  • 24.5. TxCell
    • 24.5.1 Interview Transcript
  • 24.6. Kite Pharma
    • 24.6.1. Interview Transcript
  • 24.7. Celyad
    • 24.7.1. Interview Transcript
  • 24.8. Waisman Biomanufacturing
    • 24.8.1. Interview Transcript
  • 24.9. Theravectys
    • 24.9.1. Interview Transcript
  • 24.10. Changhai Hospital
    • 24.10.1. Interview Transcript
  • 24.11. Changhai Hospital
    • 24.11.2. Interview Transcript

25. CONCLUDING REMARKS

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

28. APPENDIX III: LIST OF FUNDING AND INVESTMENTS

Show more
Product Code: RA100389

List of Tables

  • Table 5.1 Key Characteristics of CAR-T Cells
  • Table 5.2 Comparison of First and Second-Generation CAR-Ts
  • Table 6.1 CAR-T Cell Therapies: Approved and Clinical Pipeline
  • Table 6.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-cell, Dosage Regimen, and Target Patient Population
  • Table 6.3 CAR-T Cell Therapy: Preclinical Pipeline
  • Table 6.4 List of CAR-T Cells Developers
  • Table 10.1 Leading CAR-T Cell Therapy Developers
  • Table 10.2 Autolus: Company Profile
  • Table 10.3 bluebird Bio: Company Profile
  • Table 10.4 Bristol Myers Squibb: Company Profile
  • Table 10.5 CARsgen Therapeutics: Company Profile
  • Table 10.6 Cellectis: Company Profile
  • Table 10.7 Gilead Sciences: Company Profile
  • Table 10.8 Innovative Cellular Therapeutics: Company Profile
  • Table 10.9 Noile-Immune Biotech: Company Profile
  • Table 10.10 Novartis: Company Profile
  • Table 10.11 Sinobioway Cell Therapy: Company Profile
  • Table 10.12 Takara Bio: Company Profile
  • Table 10.13 Wellington Zhaotai Therapies: Company Profile
  • Table 11.1 CAR T Cell Therapy: List of Partnerships and Collaborations, 2000-2022
  • Table 12.1 CAR T Cell Therapies: Funding and Investments, 2018-2024
  • Table 12.2 CAR T Cell Therapies: Summary of Investments
  • Table 13.1 Patent Analysis: Prominent CPC Sections
  • Table 13.2 Patent Analysis: Most Popular CPC Symbols
  • Table 13.3 Patent Analysis: List of Top CPC Symbols
  • Table 13.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 14.1 Assessment Strategies for Different Manufacturing Processes
  • Table 14.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
  • Table 14.3 Cell Therapy Manufacturing: Companies with In-house Capabilities and Contract Manufacturers
  • Table 15.1 Price of Marketed Gene / Cell Therapies
  • Table 15.2 Price of Marketed Targeted Drugs
  • Table 15.3 CAR-T Cell Therapy: Expert Opinions on Pricing
  • Table 15.4 CAR-T Cell Therapy: Reimbursement Landscape
  • Table 21.1 CAR-T Cell Therapy: List of Forecasted Molecules
  • Table 25.1 CAR-T Cell Therapy: Distribution by Stage of Development
  • Table 25.2 CAR-T Cell Therapy: Distribution by Type of Therapy
  • Table 25.3 CAR-T Cell Therapy: Distribution by Target Antigen
  • Table 25.4 CAR-T Cell Therapy: Distribution by Target Indication
  • Table 25.5 CAR-T Cell Therapy: Distribution by Target Therapeutic Area
  • Table 25.6 CAR-T Cell Therapy: Distribution by Stage of Development and Therapeutic Area
  • Table 25.7 CAR-T Cell Therapy: Distribution by Source of T- cells
  • Table 25.8 CAR-T Cell Therapy: Distribution by Stage of Development and Source of T- cells
  • Table 25.9 CAR-T Cell Therapy: Distribution by Route of Administration
  • Table 25.10 CAR-T Cell Therapy: Distribution by Dosage Regimen
  • Table 25.11 CAR-T Cell Therapy: Distribution by Target Patient Population
  • Table 25.12 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
  • Table 25.13 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
  • Table 25.14 CAR-T Cell Therapy Developers Distribution by Year of Establishment
  • Table 25.15 CAR-T Cell Therapy Developers: Distribution by Company Size
  • Table 25.16 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region wise)
  • Table 25.17 CAR-T Cell Therapy: Distribution by Location of Headquarters (Country wise)
  • Table 25.18 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
  • Table 25.19 CAR-T Cell Therapies: Popular Targets in Solid Tumors
  • Table 25.20 CAR-Construction: Distribution by Generation of CAR
  • Table 25.21 CAR-Construction: Distribution by Type of scFv Antibody Used
  • Table 25.22 CAR-Construction: Distribution by Type of Virus Used
  • Table 25.23 CAR-Construction: Distribution by Type of Gene Transfer Method Used
  • Table 25.24 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
  • Table 25.25 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
  • Table 25.26 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
  • Table 25.27 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 25.28 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Phase
  • Table 25.29 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017-2024
  • Table 25.30 Clinical Trial Analysis: Distribution by Trial Status
  • Table 25.31 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 25.32 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Table 25.33 Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Table 25.34 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 25.35 Clinical Trial Analysis: Distribution by Trial Purpose
  • Table 25.36 Clinical Trial Analysis: Distribution by Design Allocation
  • Table 25.37 Leading Industry Players: Distribution by Number of Registered Trials
  • Table 25.38 Leading Non-industry Players: Distribution by Number of Registered Trials
  • Table 25.39 Clinical Trial Analysis: Distribution of Clinical Trials by Status and Geography
  • Table 25.40 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Table 25.41 KOL Analysis: Distribution by Type of Organization
  • Table 25.42 KOL Analysis: Distribution by Affiliated Organization
  • Table 25.43 KOL Analysis: Distribution by Qualification
  • Table 25.44 CAR T-Cell Therapies: Geographical Distribution of KOLs
  • Table 25.45 Most Prominent KOLs: Distribution by RA Score
  • Table 25.46 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Table 25.47 Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015-2022
  • Table 25.48 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 25.49 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
  • Table 25.50 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Table 25.51 Partnerships and Collaborations: Distribution by Type of Partner
  • Table 25.52 Partnership and Collaborations: Year-Wise Distribution by Type of Partner
  • Table 25.53 Most Popular Therapies: Distribution by Number of Partnerships
  • Table 25.54 Most Active Industry Players: Distribution by Number of Partnerships
  • Table 25.55 Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Table 25.56 Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
  • Table 25.57 Partnerships and Collaborations: Distribution by Local and International Agreements
  • Table 25.58 Funding and Investment: Cumulative Distribution of Instances by Year, Pre 2014-2024
  • Table 25.59 Funding and Investment: Cumulative Distribution of Amount Invested by Year, Pre-2014-2024 (USD Million)
  • Table 25.60 Funding and Investment: Distribution of Instances by Type of Funding
  • Table 25.61 Funding and Investment: Distribution of Total Amount Invested by Type of Funding (USD Million)
  • Table 25.62 Funding and Investment: Distribution by Amount Invested and Type of Funding Year Wise
  • Table 25.63 Funding and Investment: Distribution by Geography (Region)
  • Table 25.64 Funding and Investment: Distribution by Geography (Country)
  • Table 25.65 Most Active Players: Distribution by Lead Investors
  • Table 25.66 Most Active Players: Distribution by Number of Funding Instances
  • Table 25.67 Patent Analysis: Distribution by Type of Patent
  • Table 25.68 Patent Analysis: Distribution by Patent Publication Year, Pre-2018-2024
  • Table 25.69 Patent Analysis: Distribution by Patent Application Year
  • Table 25.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, Pre-2018-2024
  • Table 25.71 Patent Analysis: Distribution by Patent Jurisdiction
  • Table 25.72 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Table 25.73 Leading Industry Players: Distribution by Number of Patents
  • Table 25.74 Leading Non-industry Players: Distribution by Number of Patents
  • Table 25.75 Leading Individual Assignees: Distribution by Number of Patents
  • Table 25.76 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Table 25.77 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Table 25.78 Patent Analysis: Distribution by Patent Age
  • Table 25.79 CAR-T Cell Therapy: Patent Valuation
  • Table 25.80. Global CAR-T Cell Therapy Market, Conservative, Base and Optimistic Scenario, 2024-2035 (USD Million)
  • Table 25.81 CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
  • Table 25.82 CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.83 CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.84 CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.85 CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Million)
  • Table 25.86 CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Million)
  • Table 25.87 CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035 (USD Million)
  • Table 25.88 CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.89 CAR-T Cell Therapy Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.90 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.91 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.92 CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma, Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.93 CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Million)
  • Table 25.94 CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Million)
  • Table 25.95 CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.96 CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2028-2035) (USD Million)
  • Table 25.97 CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Million)
  • Table 25.98 CAR-T Cell Therapy Market for Renal transplantation: Forecasted Estimates (2030-2035) (USD Million)
  • Table 25.99 CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Million)
  • Table 25.100 CAR-T Cell Therapy Market for Ovarian and endometrial Cancer: Forecasted Estimates (2028-2035) (USD Million)
  • Table 25.101 CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Million)
  • Table 25.102 CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.103 CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2028-2035) (USD Million)
  • Table 25.104 CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024 and 2035
  • Table 25.105 CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.106 CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.107 CAR-T Cell Therapy Market in Asia Pacific: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.108 CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.109 CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.110 CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Million)
  • Table 25.111 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035(USD Million)
  • Table 25.112 CAR-T Cell Therapy Market for Yescarta (axicabtageneciloleucel): Sales Forecast, 2024-2035 (USD Million)
  • Table 25.113 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast,2024-2035 (USD Million)
  • Table 25.114 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, 2024-2035 (USD Million)
  • Table 25.115 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38MCAR-T / JNJ-68284528 /Ciltacabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
  • Table 25.116 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, 2024-2035 (USD Million)
  • Table 25.117 CAR-T Cell Therapy Market for Carteyva (Relmacabtageneautoleucel / JWCAR029): Sales Forecast, 2024-2035, (USD Million)
  • Table 25.118 CAR-T Cell Therapy Market for NexCART: Sales Forecast,2024-2035, (USD Million)
  • Table 25.119 CAR-T Cell Therapy Market for Fucaso (Equecabtagene Autoleucel): Sales Forecast,2024-2035, (USD Million)
  • Table 25.120 CAR-T Cell Therapy Market for Inaticabtagene AutoleucelCNCT19 / HY001: Sales Forecast, 2024-2035 (USD Million)
  • Table 25.121 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
  • Table 25.122 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, 2027-2035 (USD Million)
  • Table 25.123 CAR-T Cell Therapy Market for CAR-T-CD19 cells: Sales Forecast, 2026-2035 (USD Million)
  • Table 25.124 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, 2029-2035 (USD Million)
  • Table 25.125 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, 2028-2035 (USD Million)
  • Table 25.126 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, 2029-2035 (USD Million)
  • Table 25.127 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.128 CAR-T Cell Therapy Market for CT041: Sales Forecast, 2030-2035, (USD Million)
  • Table 25.129 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, 2032-2035, (USD Million)
  • Table 23.130 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast,2028-2035 (USD Million)
  • Table 25.131 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, 2029-2035 (USD Million)
  • Table 25.132 CAR-T Cell Therapy Market for AUTO1: Sales Forecast,2029-2035 (USD Million)
  • Table 25.133 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, 2025-2035 (USD Million)
  • Table 25.134 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, 2029-2035 (USD Million)
  • Table 25.135 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, 2026-2035 (USD Million)
  • Table 25.136 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.137 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, 2027-2035 (USD Million)
  • Table 25.138 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.139 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.140 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.141 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.142 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
  • Table 25.143 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
  • Table 25.144 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.145 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, 2029-2035 (USD Million)
  • Table 25.146 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T /TAA05: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.147 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, 2028-2035 (USD Million)
  • Table 25.148 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.149 CAR-T Cell Therapy Market for CTX110: Sales Forecast,2030-2035 (USD Million)
  • Table 25.150 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.151 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.152 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, 2030-2035 (USD Million)
  • Table 25.153 CAR-T Cell Therapies Market: Distribution by Key Players
  • Table 25.154 CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
  • Table 25.155 CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
  • Table 25.156 CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
  • Table 25.157 CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
  • Table 25.158 CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Research Assumptions
  • Figure 2.2 Research Methodology: Project Methodology
  • Figure 2.3 Research Methodology: Forecast Methodology
  • Figure 2.4 Research Methodology: Robust Quality Control
  • Figure 2.5 Research Methodology: Key Market Segmentations
  • Figure 3.1 Lessons Learnt from Past Recessions
  • Figure 4.1 Executive Summary: Market Landscape
  • Figure 4.2 Executive Summary: Clinical Trial Analysis
  • Figure 4.3 Executive Summary: Funding and Investments
  • Figure 4.4 Executive Summary: Patent Analysis
  • Figure 4.5 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 5.1 Strategies Employed for the Redirection of T-Cells
  • Figure 5.2 T-Cell Manufacturing: General Procedure
  • Figure 5.3 Development History of CAR-T cells
  • Figure 5.4 Structure of Chimeric Antigen Receptor
  • Figure 5.5 Chimeric Antigen Receptors: Structural Variations across Different Generations
  • Figure 5.6 CAR-T Cell Therapies: Development Process
  • Figure 5.7 Challenges Associated with CAR-T-Cell Therapies
  • Figure 6.1 CAR-T Cell Therapies: Distribution by Stage of Development
  • Figure 6.2 CAR-T Cell Therapies: Distribution by Type of Therapy
  • Figure 6.2 CAR-T Cell Therapies: Distribution by Target Antigen
  • Figure 6.3 CAR-T Cell Therapies: Distribution by Target Indication
  • Figure 6.4 CAR-T Cell Therapies: Distribution by Therapeutic Area
  • Figure 6.5 CAR-T Cell Therapies: Distribution by Stage of Development and Therapeutic Area
  • Figure 6.6 CAR-T Cell Therapies: Distribution by Source of T-cells
  • Figure 6.7 CAR-T Cell Therapies: Distribution by Stage of Development and Source of T-cells
  • Figure 6.8 CAR-T Cell Therapies: Distribution by Route of Administration
  • Figure 6.9 CAR-T Cell Therapies: Distribution by Dosage Regimen
  • Figure 6.10 CAR-T Cell Therapies: Distribution by Target Patient Population
  • Figure 6.11 Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
  • Figure 6.12 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
  • Figure 6.13 CAR-T Cell Therapies Developers: Distribution by Year of Establishment
  • Figure 6.14 CAR-T Cell Therapies Developers: Distribution by Company Size
  • Figure 6.15 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Region)
  • Figure 6.16 CAR-T Cell Therapies Developers: Distribution by Location of Headquarters (Country)
  • Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
  • Figure 7.2 CAR-T Cell Therapies: Popular Targets in Solid Tumors
  • Figure 7.3 CAR-Construction: Distribution by Generation of CAR
  • Figure 7.4 CAR-Construction: Distribution by Type of scFv Antibody
  • Figure 7.5 CAR-Construction: Distribution by Type of Virus Used
  • Figure 7.6 CAR-Construction: Distribution by Type of Gene Transfer Method Used
  • Figure 7.7 CAR-Construction: Distribution by Type of Co-Stimulatory Domain
  • Figure 8.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Pre-2017-2024
  • Figure 8.2 Clinical Trial Analysis: Year- wise Trend of Patients Enrolled by Trial Registration Year, Pre- 2017-2024
  • Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 8.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Figure 8.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase, Pre-2017-2023
  • Figure 8.6 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 8.7 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 8.8 Clinical Trial Analysis: Distribution by Therapeutic Area
  • Figure 8.9 Clinical Trial Analysis: Distribution by Type of Trial Masking
  • Figure 8.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 8.11 Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 8.12 Clinical Trial Analysis: Distribution by Design Allocation
  • Figure 8.13 Leading Industry Players: Distribution by Number of Registered Trials
  • Figure 8.14 Leading Non-Industry Players: Distribution by Number of Registered Trials
  • Figure 8.15 Clinical Trial Analysis: Distribution of Clinical Trials by Trial Status and Geography
  • Figure 8.16 Clinical Trial Analysis: Distribution of Patients Enrolled by Trial Status and Geography
  • Figure 9.1 KOL Analysis: Distribution by Type of Organization
  • Figure 9.2 KOL Analysis: Distribution by Affiliated Organization
  • Figure 9.3 KOL Analysis: Distribution by Qualification
  • Figure 9.4 CAR T-Cell Therapies: Geographical Distribution of KOLs
  • Figure 9.5 CAR T-Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
  • Figure 9.6 Most Prominent KOLs: KOL Activeness versus KOL Strength
  • Figure 9.7 Most Prominent KOLs: Distribution by RA Score
  • Figure 9.8 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Figure 9.9 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
  • Figure 11.1. Partnerships and Collaborations: Cumulative Year-wise Trend, Pre-2015- 2022
  • Figure 11.2. Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 11.4. Partnerships and Collaborations: Distribution by Type of Partner
  • Figure 11.5. Most Popular Therapies: Distribution by Number of Partnerships
  • Figure 11.6. Most Active Industry Players: Distribution by Number of Partnerships
  • Figure 11.7. Most Active Non-Industry Players: Distribution by Number of Partnerships
  • Figure 11.8. Partnerships and Collaborations: Distribution by Intracontinental and Intercontinental Agreements
  • Figure 11.8. Partnerships and Collaborations: Distribution by Local and International Agreements
  • Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend, Pre-2014-2024

Figure12.2 Funding and Investment Analysis: Distribution by Amount Invested, Pre-2014-2024 (USD Million)

Figure12.3 Funding and Investment Analysis: Distribution by Type of Funding

Figure12.4 Funding and Investment Analysis: Distribution by Amount Invested and Type of Funding (USD Million)

Figure12.5 Year-wise Distribution of Amount Invested by Type of Funding, 2018-2024

  • Figure 12.6 Funding and Investment Analysis: Distribution by Geography (Region)
  • Figure 12.7 Funding and Investment Analysis: Distribution of Funding Instances by Geography (Country)
  • Figure 12.8 Most Active Players: Distribution by Funding Instances
  • Figure 12.9 Leading Investors: Distribution by Number of Funding Instances
  • Figure 13.1 Patent Analysis: Distribution by Type of Patent
  • Figure 13.2 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2018-2024
  • Figure 13.3 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2017-2024
  • Figure 13.4 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications, 2018-2024
  • Figure 13.5 Patent Analysis: Distribution by Patent Jurisdiction
  • Figure 13.6 Patent Analysis: Distribution by CPC Symbols
  • Figure 13.7 Patent Analysis: Cumulative Year-wise Distribution by Type of Applicant
  • Figure 13.8 Leading Industry Players: Distribution by Number of Patents
  • Figure 13.9 Leading Non-industry Players: Distribution by Number of Patents
  • Figure 13.10 Leading Individual Assignees: Distribution by Number of Patents
  • Figure 13.11 Patent Benchmarking Analysis: Distribution of Patent Characteristics (CPC Codes) by Leading Industry Players
  • Figure 13.12 Patent Benchmarking Analysis: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
  • Figure 13.13 Patent Analysis: Distribution by Patent Age
  • Figure 13.14 CAR-T Cell Therapy: Patent Valuation
  • Figure 14.1 Steps for Manufacturing Cell Therapies
  • Figure 14.2 Centralized Manufacturing: Process Model
  • Figure 14.3 Decentralized Manufacturing: Process Model
  • Figure 14.4 Cell Therapy Manufacturing: Types of Manufacturers
  • Figure 14.5 Cell Therapy: Challenges and Drivers
  • Figure 14.6 Cell Therapies: Potency as Critical Quality Attribute
  • Figure 14.7 Cell Therapy Manufacturing: Supply Chain Model
  • Figure 14.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
  • Figure 15.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
  • Figure 16.1. CAR-T Cell Therapies: Market Drivers
  • Figure 16.2. CAR-T Cell Therapies: Market Restraints
  • Figure 16.3. CAR-T Cell Therapies: Market Opportunities
  • Figure 16.4. CAR-T Cell Therapies: Market Challenges
  • Figure 17.1. Global CAR-T Cell Therapy Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
  • Figure 17.2. Global CAR-T Cell Therapy Market, 2024-2035: Conservative Scenario (USD Million)
  • Figure 17.3. Global CAR-T Cell Therapy Market, 2024-2035: Optimistic Scenario (USD Million)
  • Figure 18.1. CAR-T Cell Therapy Market: Distribution by Target Antigen, 2024 and 2035
  • Figure 18.2. CAR-T Cell Therapy Market for CD19: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.3. CAR-T Cell Therapy Market for BCMA: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.4. CAR-T Cell Therapy Market for CD20: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 18.5. CAR-T Cell Therapy Market for CD19/CD22: Forecasted Estimates (2025-2035) (USD Billion)
  • Figure 18.6. CAR-T Cell Therapy Market for Other Target Antigen: Forecasted Estimates (2028-2035) (USD Billion)
  • Figure 19.1. CAR-T Cell Therapy Market: Distribution by Target Indication, 2024 and 2035
  • Figure 19.2. CAR-T Cell Therapy Market for Multiple Myeloma: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.3. CAR-T Cell Therapy Market for CAR-T Cell Therapies Market for Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.4. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.5. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.6. CAR-T Cell Therapy Market for Diffuse Large B-cell Lymphoma and Large B-cell Lymphoma: Forecasted Estimates (2024-2035 (USD Billion)
  • Figure 19.7. CAR-T Cell Therapy Market for Acute Lymphoblastic Leukemia / B-cell Non-Hodgkin Lymphoma: Forecasted Estimates (2029-2035) (USD Billion)
  • Figure 19.8. CAR-T Cell Therapy Market for Non-Hodgkin Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
  • Figure 19.9. CAR-T Cell Therapy Market for Mantle Cell Lymphoma: Forecasted Estimates (2027-2035) (USD Billion)
  • Figure 19.10. CAR-T Cell Therapy Market for Acute Myeloid Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
  • Figure 19.11. CAR-T Cell Therapy Market for Generalized Myasthenia Gravis: Forecasted Estimates (2029-2035) (USD Billion)
  • Figure 19.12. CAR-T Cell Therapy Market for Renal Transplantation: Forecasted Estimates (2030-2035) (USD Billion)
  • Figure 19.13. CAR-T Cell Therapy Market for Gastric Adenocarcinoma: Forecasted Estimates (2030-2035) (USD Billion)
  • Figure 19.14. CAR-T Cell Therapy Market for Ovarian / Endometrial Cancer: Forecasted Estimates (2028-2035) (USD Billion)
  • Figure 19.15. CAR-T Cell Therapy Market for Chronic Lymphocytic Leukemia: Forecasted Estimates (2027-2035) (USD Billion)
  • Figure 19.16. CAR-T Cell Therapy Market for Follicular Lymphoma: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 19.17. CAR-T Cell Therapy Market for Renal Cell Carcinoma: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.1. CAR-T Cell Therapy Market: Distribution by Key Geographical Regions, 2024, 2030 and 2035
  • Figure 20.2. CAR-T Cell Therapy Market in North America: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.3. CAR-T Cell Therapy Market in Europe: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.4. CAR-T Cell Therapy Market in Asia-Pacific: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.5. CAR-T Cell Therapy Market in Latin America: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.6. CAR-T Cell Therapy Market in Middle East and North Africa: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 20.7. CAR-T Cell Therapy Market in Rest of the World: Forecasted Estimates (2024-2035) (USD Billion)
  • Figure 21.1 CAR-T Cell Therapy Market for Kymriah (Tisagenlecleucel-T): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.2 CAR-T Cell Therapy Market for Yescarta (axicabtagene ciloleucel): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.3 CAR-T Cell Therapy Market for Tecartus (Brexucabtagene Autoleucel): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.4 CAR-T Cell Therapy Market for Abecma (Idecabtagene Vicleucel / bb2121): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.5 CAR-T Cell Therapy Market for CARVYKTI (LCAR-B38M CAR-T / JNJ-68284528 / Ciltacabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
  • Figure 21.6 CAR-T Cell Therapy Market for BREYANZI (Lisocabtagene maraleucel, JCAR017): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.7 CAR-T Cell Therapy Market for Carteyva (Relmacabtagene autoleucel / JWCAR029): Sales Forecast, 2024-2035, (USD Million)
  • Figure 21.8 CAR-T Cell Therapy Market for NexCART: Sales Forecast, 2024-2035, (USD Million)
  • Figure 21.9 CAR-T Cell Therapy Market for Fucaso (Equecabtagene Autoleucel): Sales Forecast, 2024-2035, (USD Million)
  • Figure 21.10 CAR-T Cell Therapy Market for Inaticabtagene Autoleucel CNCT19 / HY001: Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.11 CAR-T Cell Therapy Market for Zevorcabtagene autoleucel (CT053): Sales Forecast, 2024-2035 (USD Million)
  • Figure 21.12 CAR-T Cell Therapy Market for CAR-BCMA T cells: Sales Forecast, 2027-2035 (USD Million)
  • Figure 21.13 CAR-T Cell Therapy Market for CAR-T-CD19 cells: Sales Forecast, 2026-2035 (USD Million)
  • Figure 21.14 CAR-T Cell Therapy Market for Descartes-08: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.15 CAR-T Cell Therapy Market for Zamtocabtagene Autoleucel (MB-CART2019.1): Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.16 CAR-T Cell Therapy Market for CAR-T ddBCMA: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.17 CAR-T Cell Therapy Market for CRG-02121 cells: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.18 CAR-T Cell Therapy Market for CT041: Sales Forecast, 2030-2035, (USD Million)
  • Figure 21.19 CAR-T Cell Therapy Market for ALLO-501A / ALLO-501: Sales Forecast, 2032-2035, (USD Million)
  • Figure 21.20 CAR-T Cell Therapy Market for ALLO-605: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.21 CAR-T Cell Therapy Market for Descartes-25: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.22 CAR-T Cell Therapy Market for AUTO1: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.23 CAR-T Cell Therapy Market for AUTO3 (CD19/22 CAR-T): Sales Forecast, 2025-2035 (USD Million)
  • Figure 21.24 CAR-T Cell Therapy Market for AUTO4 (CD19/22 CAR-T): Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.25 CAR-T Cell Therapy Market for CD19-CAR-T: Sales Forecast, 2026-2035 (USD Million)
  • Figure 21.26 CAR-T Cell Therapy Market for Humanized CD19-CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.27 CAR-T Cell Therapy Market for IM19 CAR-T: Sales Forecast, 2027-2035 (USD Million)
  • Figure 21.28 CAR-T Cell Therapy Market for CCT301 CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.29 CAR-T Cell Therapy Market for CARCIK-CD19: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.30 CAR-T Cell Therapy Market for CD123 CAR-T cells: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.31 CAR-T Cell Therapy Market for BCMA CAR-T: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.32 CAR-T Cell Therapy Market for CD19/CD22-CAR-T: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.33 CAR-T Cell Therapy Market for GC012F (Dual CAR-BCMA-19): Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.34 CAR-T Cell Therapy Market for CD19/CD20-CART: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.35 CAR-T Cell Therapy Market for CD7 CAR-T: Sales Forecast, 2029-2035 (USD Million)
  • Figure 21.36 CAR-T Cell Therapy Market for Anti-FLT3 CAR-T / TAA05: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.37 CAR-T Cell Therapy Market for Anti-ALPP CAR-T Cells: Sales Forecast, 2028-2035 (USD Million)
  • Figure 21.38 CAR-T Cell Therapy Market for WU CART 007: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.39 CAR-T Cell Therapy Market for CTX110: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.40 CAR-T Cell Therapy Market for TX200-TR101: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.41 CAR-T Cell Therapy Market for ALETA-001: Sales Forecast, 2030-2035 (USD Million)
  • Figure 21.42 CAR-T Cell Therapy Market for PBCAR0191: Sales Forecast, 2030-2035 (USD Million)
  • Figure 22.1. CAR-T Cell Therapies Market: Distribution by Key Players
  • Figure 22.2. CAR-T Cell Therapies Market: Bristol Myers Squibb Sales Forecast, 2024-2035 (USD Million)
  • Figure 22.3. CAR-T Cell Therapies Market: Janssen Sales Forecast, 2024-2035 (USD Million)
  • Figure 22.4. CAR-T Cell Therapies Market: Gilead Sciences Sales Forecast, 2024-2035 (USD Million)
  • Figure 22.5. CAR-T Cell Therapies Market: JW Therapeutics Sales Forecast, 2024-2035 (USD Million)
  • Figure 22.6. CAR-T Cell Therapies Market: Novartis Sales Forecast, 2024-2035 (USD Million)
  • Figure 23.1. Channels Used for Promotional Campaigns
  • Figure 23.2. Promotional / Marketing Strategy: Product Website Analysis
  • Figure 23.3. Product Website Analysis: Kymriah, Messages for Healthcare Professionals
  • Figure 23.4. Product Website Analysis: Kymriah, Messages for Patients
  • Figure 23.5. Product Website Analysis: Kymriah, Patient Support Program
  • Figure 23.6. Product Website Analysis: Yescarta, Messages for Healthcare Professionals
  • Figure 23.7. Product Website Analysis: Yescarta, Messages for Patients
  • Figure 23.8. Product Website Analysis: Yescarta, Kite Konnect
  • Figure 23.9. Product Website Analysis: Yescarta, Platform for Referral Patient Treatment and Connecting with Treatment Center
  • Figure 23.10. Product Website Analysis: Tecartus, Messages for Healthcare Professionals
  • Figure 23.11. Product Website Analysis: Tecartus, Messages for Patients
  • Figure 23.12. Product Website Analysis: Tecartus, Kite Konnect
  • Figure 23.13. Product Website Analysis: Breyanzi, Messages for Healthcare Professional
  • Figure 23.14 Product Website Analysis: Breyanzi, Messages for Patients
  • Figure 23.15 Product Website Analysis: Breyanzi, Cell Therapy 360
  • Figure 23.16 Product Website Analysis: Abecma, Messages for Healthcare Professional
  • Figure 23.17 Product Website Analysis: Abecma, Messages for Patients
  • Figure 23.18 Product Website Analysis: Abecma, Cell Therapy 360
  • Figure 23.19 Product Website Analysis: Carvykti, Messages for Healthcare Professional
  • Figure 23.20 Product Website Analysis: Carvykti, Messages for Patients
  • Figure 23.21 Product Website Analysis: Carvykti, MyCARVYKTI
  • Figure 24.1 Concluding Remarks: Market Landscape
  • Figure 25.2 Concluding Remarks: Clinical Trial Analysis
  • Figure 25.3 Concluding Remarks: Funding and Investment Analysis
  • Figure 25.4 Concluding Remarks: Patent Analysis
  • Figure 25.5 Concluding Remarks: Market Sizing and Opportunity Analysis
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!